$OMIC
Singular Genomics Systems, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024032829 Filed on March 18, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $442.0K $1.081M $2.911M
YoY Change -48.78% 41.31% 280.52%
Cost Of Revenue $861.0K $1.538M $3.469M
YoY Change 6.69% 94.93% 339.67%
Gross Profit -$419.0K -$457.0K -$558.0K
YoY Change -848.21% 1804.17% 2225.0%
Gross Profit Margin -94.8% -42.28% -19.17%
Selling, General & Admin $14.94M $13.13M $54.48M
YoY Change 13.11% 11.82% 15.27%
% of Gross Profit
Research & Development $11.49M $11.69M $47.76M
YoY Change -6.02% 8.64% 3.39%
% of Gross Profit
Depreciation & Amortization $1.019M $977.0K $3.510M
YoY Change 28.5% 35.51% 44.39%
% of Gross Profit
Operating Expenses $26.43M $24.82M $102.2M
YoY Change 3.91% 10.3% 9.39%
Operating Profit -$26.85M -$25.28M -$102.8M
YoY Change 5.79% 12.21% 9.96%
Interest Expense $284.0K $2.032M $1.101M
YoY Change 9.65% 42.2% 44.3%
% of Operating Profit
Other Income/Expense, Net $1.824M $7.981M
YoY Change 4.53% 206.02%
Pretax Income -$25.02M -$23.25M -$94.82M
YoY Change 5.89% 10.18% 4.34%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$25.02M -$23.25M -$94.82M
YoY Change 5.89% 10.18% 4.34%
Net Earnings / Revenue -5661.54% -2150.69% -3257.3%
Basic Earnings Per Share -$0.34 -$1.30
Diluted Earnings Per Share -$0.34 -$0.32 -$1.30
COMMON SHARES
Basic Shares Outstanding 73.93M 73.38M 72.80M
Diluted Shares Outstanding 73.93M 72.80M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $151.1M $175.4M $175.4M
YoY Change -33.3% -28.47% -28.47%
Cash & Equivalents $24.11M $16.23M $16.23M
Short-Term Investments $127.0M $159.2M $159.2M
Other Short-Term Assets $2.155M $2.691M $2.691M
YoY Change -21.69% -34.4% -34.4%
Inventory $13.08M $13.57M $13.57M
Prepaid Expenses $1.116M $1.672M
Receivables $137.0K $565.0K $565.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $166.5M $192.2M $192.2M
YoY Change -32.46% -28.39% -28.39%
LONG-TERM ASSETS
Property, Plant & Equipment $13.85M $13.69M $71.49M
YoY Change 23.05% 26.97% 26.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.078M $1.150M $1.750M
YoY Change -6.42% -0.17% -38.88%
Total Long-Term Assets $72.63M $73.24M $73.24M
YoY Change 23.11% 23.0% 23.0%
TOTAL ASSETS
Total Short-Term Assets $166.5M $192.2M $192.2M
Total Long-Term Assets $72.63M $73.24M $73.24M
Total Assets $239.1M $265.5M $265.5M
YoY Change -21.73% -19.06% -19.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.012M $2.587M $2.587M
YoY Change 1.77% -16.52% -16.52%
Accrued Expenses $3.265M $6.079M $13.84M
YoY Change -2.62% 32.64% 26.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.625M $1.312M
YoY Change
Total Short-Term Liabilities $16.08M $18.29M $18.29M
YoY Change 28.73% 29.53% 29.53%
LONG-TERM LIABILITIES
Long-Term Debt $7.627M $8.901M $8.901M
YoY Change -24.51% -11.56% -11.56%
Other Long-Term Liabilities $605.0K $650.0K $59.27M
YoY Change -39.38% -35.96% 36.35%
Total Long-Term Liabilities $8.232M $9.551M $68.17M
YoY Change -25.84% -13.8% 27.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.08M $18.29M $18.29M
Total Long-Term Liabilities $8.232M $9.551M $68.17M
Total Liabilities $82.40M $86.46M $86.46M
YoY Change 26.5% 27.8% 27.8%
SHAREHOLDERS EQUITY
Retained Earnings -$362.6M -$337.6M
YoY Change 36.11% 39.04%
Common Stock $7.000K $7.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $156.7M $179.0M $179.0M
YoY Change
Total Liabilities & Shareholders Equity $239.1M $265.5M $265.5M
YoY Change -21.73% -19.06% -19.06%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$25.02M -$23.25M -$94.82M
YoY Change 5.89% 10.18% 4.34%
Depreciation, Depletion And Amortization $1.019M $977.0K $3.510M
YoY Change 28.5% 35.51% 44.39%
Cash From Operating Activities -$23.70M -$18.90M -$73.65M
YoY Change 32.17% -5.1% -15.44%
INVESTING ACTIVITIES
Capital Expenditures $25.00K $392.0K $970.0K
YoY Change -84.57% -78.44% -83.89%
Acquisitions
YoY Change
Other Investing Activities $31.60M $1.043M $14.78M
YoY Change -56.77% -47.56% -144.05%
Cash From Investing Activities $31.58M $651.0K $13.81M
YoY Change -56.71% 280.7% -134.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.000K
YoY Change -97.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 72.00K 696.0K
YoY Change -100.0% -90.4% -22.75%
NET CHANGE
Cash From Operating Activities -23.70M -18.90M -73.65M
Cash From Investing Activities 31.58M 651.0K 13.81M
Cash From Financing Activities 0.000 72.00K 696.0K
Net Change In Cash 7.876M -18.18M -59.14M
YoY Change -85.68% -4.3% -52.97%
FREE CASH FLOW
Cash From Operating Activities -$23.70M -$18.90M -$73.65M
Capital Expenditures $25.00K $392.0K $970.0K
Free Cash Flow -$23.73M -$19.29M -$74.62M
YoY Change 31.12% -11.23% -19.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001850906
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40443
CY2023 dei Entity Registrant Name
EntityRegistrantName
Singular Genomics Systems, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2948451
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
3010 Science Park Road
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2023 dei City Area Code
CityAreaCode
858
CY2023 dei Local Phone Number
LocalPhoneNumber
333-7830
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
OMIC
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
49000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73928557
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Diego, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16233000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74266000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
157708000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
170310000
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
565000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
913000
CY2023Q4 us-gaap Inventory Net
InventoryNet
13572000
CY2022Q4 us-gaap Inventory Net
InventoryNet
18221000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4150000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4722000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
192228000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
268432000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
57797000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45896000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13692000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10784000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
600000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1711000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1150000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1152000
CY2023Q4 us-gaap Assets
Assets
265467000
CY2022Q4 us-gaap Assets
Assets
327975000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2587000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3099000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6079000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4583000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7764000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6323000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1857000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
113000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18287000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14118000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58623000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42456000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8901000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10065000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
650000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1015000
CY2023Q4 us-gaap Liabilities
Liabilities
86461000
CY2022Q4 us-gaap Liabilities
Liabilities
67654000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73823161
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73823161
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71854688
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71854688
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
516439000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
503926000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
155000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-837000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337595000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242775000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
179006000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260321000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
265467000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
327975000
CY2023 us-gaap Revenues
Revenues
2911000
CY2022 us-gaap Revenues
Revenues
765000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
992000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-94820000
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
3469000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
789000
CY2023 us-gaap Gross Profit
GrossProfit
-558000
CY2022 us-gaap Gross Profit
GrossProfit
-24000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47764000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46199000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54479000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47264000
CY2023 us-gaap Operating Expenses
OperatingExpenses
102243000
CY2022 us-gaap Operating Expenses
OperatingExpenses
93463000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-102801000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-93487000
CY2023 us-gaap Interest Expense
InterestExpense
1101000
CY2022 us-gaap Interest Expense
InterestExpense
763000
CY2023 us-gaap Interest And Other Income
InterestAndOtherIncome
9082000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
3371000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7981000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2608000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-94820000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-90879000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.3
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.3
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72796250
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72796250
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71148076
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71148076
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-94820000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-90879000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
992000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-699000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93828000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91578000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
336173000
CY2022 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
705000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
172000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1180000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13669000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-699000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-90879000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260321000
CY2023 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
394000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
702000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11404000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
179006000
CY2023 us-gaap Profit Loss
ProfitLoss
-94820000
CY2022 us-gaap Profit Loss
ProfitLoss
-90879000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
11404000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
13669000
CY2023 us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
3861000
CY2022 us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
0
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3713000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3601000
CY2023 us-gaap Depreciation
Depreciation
3510000
CY2022 us-gaap Depreciation
Depreciation
2431000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1900000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
148000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
165000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1118000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-676000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-60000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-348000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
913000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3537000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13487000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-507000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-604000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
892000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
267000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1168000
CY2023 omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
1554000
CY2022 omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
79000
CY2023 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
432000
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
81000
CY2023 omic Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1866000
CY2022 omic Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1208000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
48000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
87000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73647000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87094000
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
183595000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
174713000
CY2023 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
178035000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
119647000
CY2023 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
20337000
CY2022 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
21522000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
970000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6022000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13807000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39566000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
702000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1180000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
171000
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
19000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
450000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
696000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
901000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-59144000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-125759000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75977000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201736000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16833000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75977000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
941000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
561000
CY2023 omic Lease Liability Recognized Upon Lease Modifications Furing The Period
LeaseLiabilityRecognizedUponLeaseModificationsFuringThePeriod
19475000
CY2022 omic Lease Liability Recognized Upon Lease Modifications Furing The Period
LeaseLiabilityRecognizedUponLeaseModificationsFuringThePeriod
0
CY2023 omic Inventory Transferred To Property And Equipment
InventoryTransferredToPropertyAndEquipment
7643000
CY2022 omic Inventory Transferred To Property And Equipment
InventoryTransferredToPropertyAndEquipment
104000
CY2023 omic Purchases Of Inventory Included In Accrued Expenses
PurchasesOfInventoryIncludedInAccruedExpenses
1116000
CY2022 omic Purchases Of Inventory Included In Accrued Expenses
PurchasesOfInventoryIncludedInAccruedExpenses
1601000
CY2023 omic Vesting Of Restricted Stock
VestingOfRestrictedStock
394000
CY2022 omic Vesting Of Restricted Stock
VestingOfRestrictedStock
705000
CY2023 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
24000
CY2022 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
318000
CY2023 omic Purchases Of Inventory Included In Accounts Payable
PurchasesOfInventoryIncludedInAccountsPayable
168000
CY2022 omic Purchases Of Inventory Included In Accounts Payable
PurchasesOfInventoryIncludedInAccountsPayable
226000
CY2023 omic Initial Lease Liability Recognized Upon Lease Commencements
InitialLeaseLiabilityRecognizedUponLeaseCommencements
0
CY2022 omic Initial Lease Liability Recognized Upon Lease Commencements
InitialLeaseLiabilityRecognizedUponLeaseCommencements
43231000
CY2023 omic Initial Lease Liability Recognized Upon Adoption Of Asc842
InitialLeaseLiabilityRecognizedUponAdoptionOfAsc842
0
CY2022 omic Initial Lease Liability Recognized Upon Adoption Of Asc842
InitialLeaseLiabilityRecognizedUponAdoptionOfAsc842
7074000
CY2023 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
334000
CY2023 omic Noncurrent Desposit Transferred To Property And Equipment
NoncurrentDespositTransferredToPropertyAndEquipment
0
CY2022 omic Noncurrent Desposit Transferred To Property And Equipment
NoncurrentDespositTransferredToPropertyAndEquipment
759000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74266000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337600000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242800000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
173900000
CY2023 omic Period Of Operations Sufficient To Fund
PeriodOfOperationsSufficientToFund
P12M
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16233000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
600000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1711000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16833000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75977000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
157553000
CY2023Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
155000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
157708000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
171147000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-837000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
170310000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
157540000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
155920000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
168000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
14390000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
157708000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
170310000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1900000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Revenue Recognition Allowances
RevenueRecognitionAllowances
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue from sales of its products, which consist of the G4 instrument, related consumable flow cell kits and services. Revenue from instrument sales is recognized generally upon customer acceptance. Revenue from consumables sales is recognized generally upon shipment to the customer. Revenue from services, which are primarily comprised of assurance-type services, is recognized over the applicable service period.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recorded net of discounts and sales taxes. The Company invoices its customers for instruments generally upon acceptance, for consumables generally on delivery, and for services generally in advance of the service period. Invoice terms are generally net 30 days. Cash received from customers in advance of revenue recognition is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company regularly enters into contracts that include a combination of products and services, which are distinct within the context of the contract and are accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. Until the Company has sufficient volume of historical sales data for each performance obligation, the Company determines the standalone selling price using observable prices when available and with consideration of current market conditions which is primarily based on prices set by management, adjusted for applicable discounts. The Company then recognizes revenue for each performance obligation as that performance obligations is satisfied as discussed above.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into instrument arrangements with certain customers, under which the Company provides the G4 instrument at no cost to the customer, other than shipping, and the customer pays for consumables at list price, or at list price plus a mark-up, as consumables are ordered, shipped and invoiced. Revenue is recognized as consumables are shipped to the customer and disclosed within consumables revenue below. The G4 instrument provided to the customer is recorded on the balance sheet as property and equipment and disclosed as instruments at customer sites under Note 6 to these financial statements. Revenue associated with any lease elements of these arrangements was not material during the years ended December 31, 2023 and 2022.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue related to sales of instruments and consumables products, respectively. Contract liabilities, which consists of deferred revenue, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, were recorded as other noncurrent liabilities. Deferred revenue represents the value of performance obligations that have been invoiced but for which revenue has not yet been earned.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023 and 2022, all of the Company’s revenue was generated within the United Sates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the period, the Company generated approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue from its top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
300000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
100000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
7100000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6400000
CY2022Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
700000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
11627000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
14508000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1276000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3276000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
669000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
437000
CY2023Q4 us-gaap Inventory Net
InventoryNet
13572000
CY2022Q4 us-gaap Inventory Net
InventoryNet
18221000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1672000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3003000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
1019000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
1099000
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1459000
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
620000
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4150000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4722000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21713000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15342000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8021000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4558000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13692000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10784000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1900000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5229000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3580000
CY2023Q4 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
264000
CY2022Q4 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
360000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
178000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
204000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
408000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
439000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6079000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4583000
CY2021Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
15000000
CY2023 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-09-01
CY2023 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0075
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.04
CY2023 omic Debt Instrument Interest Rate Due On Maturity Date
DebtInstrumentInterestRateDueOnMaturityDate
0.04
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
287000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
435000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10213000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10065000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1312000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8901000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10065000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2206000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5886000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4510000
CY2023Q4 omic Long Term Debt Maturities Repayments Of Principal Including Interest Payments
LongTermDebtMaturitiesRepaymentsOfPrincipalIncludingInterestPayments
12602000
CY2023Q4 omic Interest And Final Payment Fee
InterestAndFinalPaymentFee
2102000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
287000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10213000
CY2023Q4 omic Accrued Payment Related To Milestone
AccruedPaymentRelatedToMilestone
400000
CY2022Q4 omic Accrued Payment Related To Milestone
AccruedPaymentRelatedToMilestone
400000
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
1100000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.036
CY2022Q1 omic Cash Payments
CashPayments
7500000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.097
CY2023Q4 omic Cash Payments
CashPayments
118900000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2022Q4 omic Cash Payments
CashPayments
86700000
CY2023 us-gaap Operating Leases Income Statement Initial Direct Costs
OperatingLeasesIncomeStatementInitialDirectCosts
11800000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
3500000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
8300000
CY2022 us-gaap Operating Leases Income Statement Initial Direct Costs
OperatingLeasesIncomeStatementInitialDirectCosts
9300000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
100000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
2700000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
6500000
CY2023Q4 us-gaap Liabilities Subject To Compromise Capital Lease Obligations And Accrued Interest
LiabilitiesSubjectToCompromiseCapitalLeaseObligationsAndAccruedInterest
19500000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8094000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5716000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8607000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8580000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8837000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
79058000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
118892000
CY2023Q4 omic Operating Lease Future Minimum Payments Less Discount
OperatingLeaseFutureMinimumPaymentsLessDiscount
52505000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
66387000
CY2023Q4 omic Less Current Portion
LessCurrentPortion
7764000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58623000
CY2022Q1 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
0.0001
CY2022Q1 omic Percentage Of Amended Shares Of Common Stock
PercentageOfAmendedSharesOfCommonStock
0.049
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9637022
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.35
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4066881
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.17
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3167750
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.08
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23479
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.56
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1029544
CY2023 omic Share Based Compensation Arrangements By Share Based Payment Award Options Forfeited In Period Weighted Average Forfeiture Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageForfeiturePrice
5.56
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11751749
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.19
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
93000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6045163
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.55
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
52000
CY2023Q4 omic Liability For Cash Received From Early Exercise Of Stock
LiabilityForCashReceivedFromEarlyExerciseOfStock
100000
CY2022Q4 omic Liability For Cash Received From Early Exercise Of Stock
LiabilityForCashReceivedFromEarlyExerciseOfStock
500000
CY2023Q4 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
34384
CY2022Q4 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
526660
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11404000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13669000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
19500000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
54252000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40101000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7247
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5756
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0415
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0198
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20180834
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19912000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19085000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4422000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2615000
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-3945000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-3434000
CY2023 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
26988000
CY2022 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
24423000
CY2023 omic Effective Income Tax Rate Reconciliation Permanent Items And Other Amount
EffectiveIncomeTaxRateReconciliationPermanentItemsAndOtherAmount
1291000
CY2022 omic Effective Income Tax Rate Reconciliation Permanent Items And Other Amount
EffectiveIncomeTaxRateReconciliationPermanentItemsAndOtherAmount
711000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
13371000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9433000
CY2023Q4 omic Lease Liability
LeaseLiability
15193000
CY2022Q4 omic Lease Liability
LeaseLiability
11673000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
13765000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
7408000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5338000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3972000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
101919000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
72587000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
86196000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59435000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15723000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
13152000
CY2023Q4 omic Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
-13227000
CY2022Q4 omic Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
-10983000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2496000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2169000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
15723000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
13152000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
26800000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
24600000
CY2023 omic Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2023 omic Period For Cumulative Change In Ownership
PeriodForCumulativeChangeInOwnership
P3Y
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1237000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
866000
CY2023 omic Unrecognizedtaxbenefitsincreasesdecreaseresultingfrompriorperiodtaxpositions
Unrecognizedtaxbenefitsincreasesdecreaseresultingfrompriorperiodtaxpositions
50000
CY2022 omic Unrecognizedtaxbenefitsincreasesdecreaseresultingfrompriorperiodtaxpositions
Unrecognizedtaxbenefitsincreasesdecreaseresultingfrompriorperiodtaxpositions
-50000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
936000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
421000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2223000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1237000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18363582
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12663682
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-032829-index-headers.html Edgar Link pending
0000950170-24-032829-index.html Edgar Link pending
0000950170-24-032829.txt Edgar Link pending
0000950170-24-032829-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omic-20231231.htm Edgar Link pending
omic-20231231.xsd Edgar Link pending
omic-ex23_1.htm Edgar Link pending
omic-ex31_1.htm Edgar Link pending
omic-ex31_2.htm Edgar Link pending
omic-ex32_1.htm Edgar Link pending
omic-ex32_2.htm Edgar Link pending
omic-ex97_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
omic-20231231_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending